IR Insights: Recapping Moderna’s ASCO 2026 Oral Presentation – 5-Year Update of the Phase 2 KEYNOTE-942 Study

Earlier today, Moderna and Merck presented 5-year follow-up data for intismeran autogene in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel and Chief Development Officer David Berman about these results.

Stay tuned for more updates and follow us on LinkedIn and X to learn more about Moderna and how we’re changing the future of medicine.

Forward-Looking Statements

This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the ability of intismeran autogene in combination with pembrolizumab to demonstrate sustained improvement in RFS and DMFS compared with pembrolizumab alone; the encouraging trend in overall survival compared with pembrolizumab alone; the mechanism of action of intismeran; the potential for Moderna to enter a new therapeutic area in cancer; Moderna’s Phase 3 trial in melanoma; and anticipated progress and milestones for Moderna’s pipeline programs, including potential near-term data and other catalysts. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this post.